U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07776054) titled 'Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF' on Aug. 17.
Brief Summary: SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be ran...